Histamine is a biogenic amine that plays multifaceted roles in both the peripheral and central nervous systems, with growing evidence supporting its significance in neurodegenerative disease pathogenesis and therapy. Originally discovered as a chemical mediator of allergic reactions, histamine's role has expanded to encompass neurotransmission, neuroinflammation, and modulation of protein aggregation processes critical to diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This comprehensive review examines the biology of histamine, its receptors and signaling pathways, and its complex involvement in neurodegenerative disorders, highlighting emerging therapeutic strategies that target the histaminergic system. [@bhowmik2012]
Histamine is a biogenic amine that plays multifaceted roles in both the peripheral and central nervous systems, with growing evidence supporting its significance in neurodegenerative disease pathogenesis and therapy. Originally discovered as a chemical mediator of allergic reactions, histamine's role has expanded to encompass neurotransmission, neuroinflammation, and modulation of protein aggregation processes critical to diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This comprehensive review examines the biology of histamine, its receptors and signaling pathways, and its complex involvement in neurodegenerative disorders, highlighting emerging therapeutic strategies that target the histaminergic system. [@bhowmik2012]
Histamine (2-imidazol-4-yl-ethylamine) is a small molecular weight amine (molecular formula C₅H₉N3, molecular weight 111 Da) synthesized from the amino acid L-histidine by the enzyme histidine decarboxylase (HDC). It functions as both a local chemical messenger and a neurotransmitter in the central nervous system (CNS), where it modulates arousal, wakefulness, appetite, memory consolidation, and immune responses [1](https://pubmed.ncbi.nlm.nih.gov/12558720/). The histaminergic system in the brain originates from the tuberomammillary nucleus (TMN) of the posterior hypothalamus, which projects widely to virtually all brain regions, establishing histamine as a globally acting neuromodulatory system [2](https://pubmed.ncbi.nlm.nih.gov/14657160/). [@zhang2008]
In the periphery, histamine is primarily stored in mast cells and basophils, where it is released in response to allergen exposure, tissue injury, and various immunological stimuli. However, in the CNS, histamine acts as a true neurotransmitter/neuromodulator, with histaminergic [neurons](/entities/neurons) exhibiting spontaneous firing patterns that correlate with arousal states and encode information about behavioral context [3](https://pubmed.ncbi.nlm.nih.gov/15233988/). This dual nature—as an immune mediator and a central neurotransmitter—places histamine at the intersection of neuroinflammation and neurodegeneration, making it a compelling target for therapeutic intervention in neurodegenerative diseases. [@arrang1983]
Histamine synthesis occurs through a single enzymatic step catalyzed by histidine decarboxylase (HDC; EC 4.1.1.107), which decarboxylates the amino acid L-histidine to produce histamine and carbon dioxide. HDC is a pyridoxal phosphate-dependent enzyme expressed predominantly in histaminergic neurons of the tuberomammillary nucleus, as well as in mast cells, basophils, gastric enterochromaffin-like cells, and certain neurons in the peripheral nervous system [4](https://pubmed.ncbi.nlm.nih.gov/10878705/). The activity of HDC is the rate-limiting step in histamine biosynthesis, and its expression is regulated at both transcriptional and post-translational levels by various physiological and pharmacological stimuli. [@brioni2011]
The gene encoding HDC (HDC) is located on chromosome 15q25.2 in humans and contains multiple single nucleotide polymorphisms (SNPs) that have been investigated for associations with neuropsychiatric and neurodegenerative conditions. Notably, a functional SNP in the HDC promoter region (rs17743449) has been associated with an increased risk of Parkinson's disease in some populations, suggesting that altered histamine biosynthesis may influence disease susceptibility [5](https://pubmed.ncbi.nlm.nih.gov/19443575/). [@nakamura2019]
In the CNS, histamine is stored in synaptic vesicles within the axon terminals of histaminergic neurons. Unlike classical neurotransmitters that are synthesized at the terminal, histamine is synthesized in the neuronal cell body and transported to terminals via the vesicular monoamine transporter 2 (VMAT2), which has affinity for histamine in addition to dopamine, norepinephrine, and serotonin [6](https://pubmed.ncbi.nlm.nih.gov/11576018/). This vesicular storage allows for rapid, activity-dependent release upon neuronal depolarization. [@oda2005]
Release of histamine from mast cells and basophils follows a fundamentally different mechanism involving antigen-mediated cross-linking of IgE receptors (FcεRI), which triggers degranulation and the rapid release of pre-formed histamine within seconds. This explosive release is distinct from the regulated exocytosis observed in neuronal histamine release and results in the systemic effects associated with allergic reactions. [@zampeli2009]
Histamine is metabolized primarily through two pathways: oxidative deamination by diamine oxidase (DAO; also known as histaminase) and methylation by histamine N-methyltransferase (HNMT). DAO is the primary enzyme for peripheral histamine catabolism, converting histamine to imidazole acetaldehyde, which is subsequently oxidized to imidazole acetic acid by aldehyde dehydrogenase. HNMT, which is predominantly expressed in the CNS, methylates histamine to tele-methylhistamine, which can be further metabolized to tele-methylimidazole acetic acid [7](https://pubmed.ncbi.nlm.nih.gov/124函5850/). [@machadofilho2004]
The activity of these catabolic enzymes has clinical relevance, as DAO deficiency has been implicated in histamine intolerance, a condition characterized by adverse reactions to histamine-rich foods. Similarly, genetic variations in HNMT have been associated with altered histamine tone and may influence susceptibility to neurodegenerative diseases through mechanisms that remain under investigation. [@cao2012]
Histamine exerts its effects through four G protein-coupled receptors (GPCRs), designated H1R, H2R, H3R, and H4R, each with distinct signaling pathways, tissue distributions, and pharmacological profiles. Understanding receptor-specific signaling is crucial for developing targeted therapeutic interventions. [@huang2013]
The H1 receptor (HRH1) is a Gαq/11-coupled GPCR that activates phospholipase C (PLC), leading to inositol trisphosphate (IP₃) and diacylglycerol (DAG) production, calcium mobilization, and protein kinase C (PKC) activation. H1R is widely expressed throughout the brain, with particularly high densities in the thalamus, hypothalamus, [cortex](/brain-regions/cortex), and [hippocampus](/brain-regions/hippocampus) [8](https://pubmed.ncbi.nlm.nih.gov/10993476/). This distribution underlies histamine's role in arousal, attention, and memory processes. [@weinreb2016]
In the context of neurodegeneration, H1R activation has been implicated in several pathological processes. In Alzheimer's disease, H1R activation on [microglia](/cell-types/microglia-neuroinflammation) can enhance the production of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), potentially accelerating neuroinflammation [9](https://pubmed.ncbi.nlm.nih.gov/20190127/). Furthermore, H1R signaling can modulate amyloid-β (Aβ) production by affecting [amyloid precursor protein](/entities/app-protein) (APP) processing through mechanisms involving PKC and mitogen-activated protein kinase (MAPK) pathways. [@ryu2009]
Paradoxically, H1R antagonists (first-generation antihistamines) have been associated with cognitive impairment in elderly patients, possibly due to central anticholinergic effects rather than histamine receptor blockade per se. Second-generation antihistamines that poorly cross the [blood-brain barrier](/entities/blood-brain-barrier) (BBB) have largely mitigated this concern. [@yanovsky2011]
The H2 receptor (HRH2) couples to Gαs proteins, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP) levels. H2R is expressed in various brain regions, including the basal ganglia, hippocampus, and cerebral cortex, where it modulates neuronal excitability and regulates the release of other neurotransmitters, including dopamine and [acetylcholine](/entities/acetylcholine) [10](https://pubmed.ncbi.nlm.nih.gov/11027816/). [@chen2009]
H2R has been implicated in neuroprotection through several mechanisms. H2R activation can increase cAMP levels in neurons, promoting cell survival through protein kinase A (PKA)-dependent pathways. Additionally, H2R signaling has been shown to reduce glutamate-induced excitotoxicity in vitro, suggesting potential therapeutic applications in conditions involving excessive glutamatergic transmission [11](https://pubmed.ncbi.nlm.nih.gov/17374477/). [@gregoric2015]
The H2R antagonist cimetidine, originally developed for gastric acid reduction, has shown neuroprotective properties in various experimental models. Studies have demonstrated that cimetidine can reduce nigrostriatal dopaminergic neurodegeneration in animal models of Parkinson's disease, possibly through antioxidant mechanisms or modulation of histamine-mediated neuroinflammation [12](https://pubmed.ncbi.nlm.nih.gov/18093344/). [@de2020]
The H3 receptor (HRH3) is uniquely positioned as both an autoreceptor that regulates histamine release and a heteroreceptor that modulates the release of other neurotransmitters, including dopamine, norepinephrine, acetylcholine, and γ-aminobutyric acid (GABA) [13](https://pubmed.ncbi.nlm.nih.gov/12629554/). H3R exhibits constitutive activity in the absence of ligand binding, making it an attractive target for inverse agonists that reduce baseline receptor signaling. [@juranek2007]
H3R is predominantly expressed in brain regions involved in motor control, cognition, and reward, including the striatum, substantia nigra, hippocampus, and cerebral cortex. This distribution has generated significant interest in H3R antagonists as potential treatments for narcolepsy, cognitive disorders, and neurodegenerative diseases [14](https://pubmed.ncbi.nlm.nih.gov/19515013/). [@liu2014]
In Parkinson's disease, H3R antagonists have shown promise in preclinical models by increasing dopaminergic tone in the striatum. The compound pitolisant (BF2.649), an H3R antagonist/inverse agonist approved for narcolepsy, has been investigated for potential benefits in PD-related fatigue and cognitive impairment [15](https://pubmed.ncbi.nlm.nih.gov/29235902/). Additionally, H3R antagonists have demonstrated anti-inflammatory effects in microglial cell cultures, suggesting potential disease-modifying properties in neurodegenerative conditions characterized by neuroinflammation. [@f2015]
The H4 receptor (HRH4) is the most recently identified histamine receptor and is expressed primarily in immune cells, including mast cells, eosinophils, dendritic cells, and T cells [16](https://pubmed.ncbi.nlm.nih.gov/16767798/). Its expression in the CNS is more limited, though some studies have reported H4R presence in the hippocampus and cerebellum. [@bae2013]
H4R plays a crucial role in modulating immune cell function and inflammatory responses. H4R activation on mast cells enhances chemotaxis and cytokine release, while on T cells, it influences Th2 differentiation and cytokine production. Given the central role of neuroinflammation in neurodegenerative diseases, H4R represents an attractive target for immunomodulatory therapies [17](https://pubmed.ncbi.nlm.nih.gov/22150550/). [@dong2014]
The therapeutic potential of H4R antagonists in neurodegeneration is an emerging area of research. Preclinical studies have suggested that H4R blockade can reduce neuroinflammation and improve outcomes in models of multiple sclerosis and traumatic brain injury, although direct evidence in AD and PD remains limited. [@barataantunes2017]
The histaminergic system undergoes significant alterations in Alzheimer's disease, with changes observed in histamine levels, receptor expression, and neuronal integrity in affected brain regions. Post-mortem studies have revealed increased histamine levels in the temporal cortex and hippocampus of AD patients, possibly reflecting reactive gliosis and increased mast cell infiltration [18](https://pubmed.ncbi.nlm.nih.gov/14736955/). However, the functional significance of this elevation remains unclear, as it may represent a compensatory response or a pathological process. [@altorres2014]
Changes in H1R and H3R expression have been reported in AD brain tissue, with some studies demonstrating increased H1R density in the frontal cortex and altered H3R signaling in the hippocampus. These modifications may contribute to the sleep disturbances, circadian rhythm disruptions, and cognitive deficits characteristic of AD [19](https://pubmed.ncbi.nlm.nih.gov/19296630/). [@mahler2013]
Emerging evidence suggests that histamine may influence key pathological hallmarks of AD. In vitro studies have demonstrated that H1R activation can increase amyloid-β production through mechanisms involving PKC and MAPK signaling pathways [20](https://pubmed.ncbi.nlm.nih.gov/17274964/). Conversely, H2R and H3R activation may have protective effects by reducing [Aβ](/proteins/amyloid-beta)-induced neurotoxicity and modulating microglial activation. [@wu2018]
The relationship between antihistamine use and cognitive outcomes in AD remains controversial. While some epidemiological studies have suggested that long-term use of first-generation antihistamines may increase dementia risk, these findings are confounded by the anticholinergic properties of these compounds rather than specific histamine receptor effects [21](https://pubmed.ncbi.nlm.nih.gov/25740586/). [@lin2009]
The involvement of the histaminergic system in Parkinson's disease has received considerable attention, particularly given the interactions between histamine and dopaminergic neurotransmission. The substantia nigra pars compacta (SNc), which undergoes degeneration in PD, receives dense histaminergic innervation, and histamine can modulate dopaminergic neuron activity through H3R and H1R signaling [22](https://pubmed.ncbi.nlm.nih.gov/19052731/). [@btry2020]
Post-mortem studies have revealed increased histamine levels and H1R/H3R density in the substantia nigra and striatum of PD patients, suggesting hyperactivity of the histaminergic system [23](https://pubmed.ncbi.nlm.nih.gov/19149715/). This hyperactivity may contribute to motor dysfunction through several mechanisms: H1R activation can inhibit dopamine release in the striatum, while H3R autoreceptor activation reduces histamine release, potentially creating a dysregulated feedback loop. [@kashida2018]
Genetic evidence supports a role for histamine in PD susceptibility. Polymorphisms in the HDC gene, which encodes histidine decarboxylase, have been associated with increased PD risk in genome-wide association studies [24](https://pubmed.ncbi.nlm.nih.gov/19443575/). Additionally, rare mutations in the HDC gene have been identified in patients with early-onset PD, suggesting that impaired histamine biosynthesis may be pathogenic in some cases [25](https://pubmed.ncbi.nlm.nih.gov/26215898/). [@bitner2009]
Clinical studies have demonstrated that H3R antagonists can improve motor symptoms in PD patients. Pitolisant, the H3R antagonist approved for narcolepsy, has shown modest benefits in reducing daytime sleepiness and fatigue in PD, though effects on motor symptoms have been variable [26](https://pubmed.ncbi.nlm.nih.gov/32054133/). [@xie2013]
The role of histamine in amyotrophic lateral sclerosis (ALS) is less well-characterized but emerging evidence suggests involvement in disease pathogenesis. Post-mortem studies have reported increased histamine levels in the motor cortex and spinal cord of ALS patients, along with alterations in H1R and H3R expression [27](https://pubmed.ncbi.nlm.nih.gov/20490473/). [@nonnekes2020]
In the SOD1 G93A mouse model of ALS, histamine levels increase in the spinal cord during disease progression, and pharmacological blockade of H1R with pyrilamine has been shown to delay disease onset and extend survival [28](https://pubmed.ncbi.nlm.nih.gov/25480780/). These findings suggest that H1R-mediated neuroinflammation may contribute to motor neuron degeneration in ALS.
The H3R has also been investigated as a potential therapeutic target in ALS. Preclinical studies have demonstrated that H3R activation can modulate glutamate release, and H3R antagonists may have beneficial effects by reducing excitotoxic mechanisms in ALS [29](https://pubmed.ncbi.nlm.nih.gov/26523703/).
Neuroinflammation is a hallmark of neurodegenerative diseases, and histamine plays a central role in modulating inflammatory responses in the CNS. Microglia, the resident immune cells of the brain, express all four histamine receptors and respond to histamine in ways that can promote or resolve neuroinflammation depending on receptor subtype and context.
H1R activation on microglia promotes a pro-inflammatory phenotype, characterized by increased production of nitric oxide (NO), prostaglandin E2 (PGE2), and cytokines including IL-1β, IL-6, and TNF-α [30](https://pubmed.ncbi.nlm.nih.gov/20190127/). This activation occurs through PKC and MAPK signaling pathways and can be enhanced by the presence of Aβ or α-synuclein aggregates, creating a feed-forward loop between protein pathology and neuroinflammation.
H2R signaling generally exerts anti-inflammatory effects in microglia through cAMP-dependent mechanisms. H2R activation can reduce the production of pro-inflammatory mediators and promote the expression of anti-inflammatory cytokines such as IL-10 [31](https://pubmed.ncbi.nlm.nih.gov/19085461/). This anti-inflammatory profile suggests potential therapeutic applications for H2R agonists in neurodegenerative diseases.
H3R functions primarily as an autoreceptor on histaminergic neurons but is also expressed on microglia, where its activation can modulate cytokine production. The constitutive activity of H3R adds complexity to therapeutic targeting, as both antagonists and inverse agonists may have beneficial effects depending on the specific disease context [32](https://pubmed.ncbi.nlm.nih.gov/22907474/).
H4R expression on immune cells makes it a key player in peripheral immune modulation that may influence CNS inflammation through various pathways, including the entry of peripheral immune cells into the brain parenchyma when BBB integrity is compromised.
A critical area of investigation concerns the potential interactions between histamine and the protein aggregation processes that underlie neurodegenerative diseases. Both Aβ in AD and α-synuclein in PD can self-assemble into oligomers and fibrils that are toxic to neurons, and histamine may influence these aggregation processes through several mechanisms.
In vitro studies have demonstrated that histamine can interact with Aβ peptides and modulate their aggregation kinetics. At physiological concentrations, histamine appears to inhibit Aβ fibril formation while promoting the formation of less toxic oligomeric species [33](https://pubmed.ncbi.nlm.nih.gov/20697123/). This modulatory effect may have complex consequences for neuronal viability, as oligomers are considered more toxic than mature fibrils in many models.
For α-synuclein, histamine has been shown to reduce aggregation in cell-free systems, possibly through direct interaction with the N-terminal region of the protein [34](https://pubmed.ncbi.nlm.nih.gov/23615738/). Whether this effect translates to meaningful neuroprotection in vivo remains to be established.
Histamine may also influence protein clearance mechanisms relevant to neurodegenerative diseases. [Autophagy](/entities/autophagy), the process by which cells degrade damaged organelles and protein aggregates, can be modulated by histamine signaling. H1R activation has been shown to inhibit autophagy, while H2R and H3R signaling can promote autophagic flux [35](https://pubmed.ncbi.nlm.nih.gov/26297958/). Given the importance of autophagy impairment in AD and PD, these receptor-specific effects may have therapeutic implications.
The H3R antagonist pitolisant (Wakix®) has emerged as the leading histamine-based therapy for neurodegenerative diseases. Approved for the treatment of narcolepsy in Europe and the United States, pitolisant increases histamine release by blocking H3R autoreceptors, thereby promoting wakefulness and cognitive arousal [36](https://pubmed.ncbi.nlm.nih.gov/25962950/).
Clinical trials have investigated pitolisant in Parkinson's disease, with mixed results regarding motor symptoms but promising effects on non-motor symptoms including fatigue, excessive daytime sleepiness, and cognitive impairment [37](https://pubmed.ncbi.nlm.nih.gov/32054133/). The drug's ability to improve alertness without the cardiovascular side effects of traditional stimulants makes it attractive for PD patients who often experience sleep disturbances.
In Alzheimer's disease, pitolisant has been investigated for the treatment of cognitive dysfunction and behavioral symptoms. Early-phase trials suggested potential benefits for attention and memory, though larger studies are needed to confirm efficacy [38](https://pubmed.ncbi.nlm.nih.gov/26968542/).
Several other H3R antagonists are in development for neurodegenerative diseases, including AZD0328, which has shown procognitive effects in preclinical models of AD [39](https://pubmed.ncbi.nlm.nih.gov/17274861/).
The role of H1R in neurodegeneration is complex, with both pro-inflammatory and potential protective effects depending on the specific context. While H1R antagonists have shown anti-inflammatory benefits in some models, their use in neurodegeneration is limited by the risk of cognitive impairment with first-generation compounds that cross the BBB.
Selective H1R agonists that poorly penetrate the BBB might theoretically provide peripheral anti-inflammatory benefits without central effects, though such compounds have not been extensively studied in neurodegenerative contexts.
Given the multifaceted involvement of histamine in neurodegeneration, combination approaches targeting multiple receptor subtypes may prove more effective than single-receptor strategies. For example, simultaneous H1R blockade and H3R activation could theoretically reduce neuroinflammation while enhancing cognitive arousal.
Histamine-based combination therapies with other neurotransmitter systems represent another promising avenue. The interactions between histamine and dopamine, acetylcholine, and glutamate suggest potential synergies that could be exploited for therapeutic benefit.
Sleep disturbances are among the earliest and most disabling non-motor symptoms in neurodegenerative diseases, affecting over 50% of AD patients and up to 90% of PD patients. The histaminergic system plays a central role in sleep-wake regulation, with histamine promoting wakefulness and H3R antagonists enhancing arousal.
In AD, sleep disruption correlates with disease severity and may accelerate cognitive decline through effects on amyloid clearance. The [glymphatic system](/entities/glymphatic-system), which clears metabolic waste from the brain, operates primarily during sleep, and impaired sleep may reduce clearance of Aβ and [tau](/proteins/tau) [40](https://pubmed.ncbi.nlm.nih.gov/25082824/).
PD patients commonly experience REM sleep behavior disorder (RBD), insomnia, and excessive daytime sleepiness. Histamine dysfunction may contribute to these symptoms, and H3R antagonists like pitolisant have shown benefits for daytime sleepiness in PD [41](https://pubmed.ncbi.nlm.nih.gov/29235902/).
Understanding of the histaminergic system's role in neurodegeneration continues to evolve, with several key questions remaining to be addressed:
Histamine occupies a unique position at the nexus of neurotransmission and neuroinflammation, making it a compelling target for neurodegenerative disease therapy. The widespread projections of histaminergic neurons throughout the brain, combined with receptor-specific effects on neuronal survival, protein aggregation, and inflammatory responses, provide multiple therapeutic entry points. While H3R antagonists like pitolisant have shown promise in clinical trials, the full therapeutic potential of histamine modulation in AD, PD, and related disorders remains to be realized. Continued research into the basic biology of histamine in neurodegeneration, coupled with well-designed clinical trials, may yield novel treatments that address the cognitive, motor, and behavioral symptoms that define these devastating diseases.
The following diagram shows the key molecular relationships involving Histamine discovered through SciDEX knowledge graph analysis: